Company intelligence / Profile preview

Neopharma

Abu Dhabi, Abu Dhabi, United Arab Emirates
Ownership
Private
Development stage
Commercial
01

Overview

Manufactures and commercializes more than 100 molecules in 50 countries with five globally accredited pharmaceutical manufacturing facilities across three continents

Therapeutic areas
Men's HealthPulmonologyEndocrinologyWomen's HealthOtherDermatologyGastroenterologyCardiovascularNeurologyInfectious Diseases
Modalities
Small moleculesgenericsbranded formulationsactive pharmaceutical ingredients (APIs)
Industry
Biotech
02

Drug pipeline

1 asset

NP-E7LP

Unknown
03

Partnerships

Japanese partnerships for diabetes research

Beyond the preview

Go deeper on Neopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neopharma.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call